The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market was valued at $81,291 million in 2016 and is estimated to reach at $178,863 million by 2023, registering a CAGR of 11.9% from 2017 to 2023.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and others. Region wise, it is analyzed across the North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Application
By Top Selling Drugs
By Region
The list of key players operating in this market include:
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market share analysis, 2016
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions and collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economics
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Other cancers
4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region
5.16. Other drugs
5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe Cancer Therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle-East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. CANCER THERAPEUTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. CANCER THERAPEUTICS MARKET FOR OTHER CANCERS, BY REGION, 2016-2023 ($MILLION)
TABLE 09. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 10. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 21. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 24. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 25. CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 31. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 32. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 41. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 47. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 48. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. LAMEA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 53. ABBVIE: COMPANY SNAPSHOT
TABLE 54. ABBVIE: OPERATING SEGMENTS
TABLE 55. ASTELLAS: COMPANY SNAPSHOT
TABLE 56. ASTELLAS: OPERATING SEGMENTS
TABLE 57. BMS: COMPANY SNAPSHOT
TABLE 58. BMS: OPERATING SEGMENTS
TABLE 59. CELGENE: COMPANY SNAPSHOT
TABLE 60. CELGENE: OPERATING SEGMENTS
TABLE 61. ELI LILLY: COMPANY SNAPSHOT
TABLE 62. ELI LILLY: OPERATING SEGMENTS
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENTS
TABLE 65. J&J: COMPANY SNAPSHOT
TABLE 66. J&J: OPERATING SEGMENTS
TABLE 67. MERCK: COMPANY SNAPSHOT
TABLE 68. MERCK: OPERATING SEGMENTS
TABLE 69. NOVARTIS: COMPANY SNAPSHOT
TABLE 70. NOVARTIS: OPERATING SEGMENTS
TABLE 71. PFIZER: COMPANY SNAPSHOT
TABLE 72. PFIZER: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 01. CANCER THERAPEUTICS MARKET: SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2018*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016-2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2016
FIGURE 07. BARGAINING POWER OF BUYERS: LOW
FIGURE 08. BARGAINING POWER OF SUPPLIERS: MODERATE
FIGURE 09. THREAT OF NEW ENTRANTS: MODERATE
FIGURE 10. THREAT OF SUBSTITUTION: HIGH
FIGURE 11. COMPETITIVE RIVALRY: HIGH
FIGURE 12. CANCER THERAPEUTICS MARKET: IMPACT ANALYSES
FIGURE 13. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (MEN)
FIGURE 14. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (WOMEN)
FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR BLOOD CANCER, 2016 AND 2023 ($MILLION)
FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR LUNG CANCER, 2016 AND 2023 ($MILLION)
FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR BREAST CANCER, 2016 AND 2023 ($MILLION)
FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR COLORECTAL CANCER, 2016 AND 2023 ($MILLION)
FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR PROSTATE CANCER, 2016 AND 2023 ($MILLION)
FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR PROSTATE CANCER, 2016 AND 2023 ($MILLION)
FIGURE 21. COMPARATIVE REGION ANALYSIS OF REVLIMID CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 22. COMPARATIVE REGION ANALYSIS OF AVASTIN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 23. COMPARATIVE REGION ANALYSIS OF HERCEPTIN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 24. COMPARATIVE REGION ANALYSIS OF RITUXAN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 25. COMPARATIVE REGION ANALYSIS OF OPDIVO CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 26. COMPARATIVE REGION ANALYSIS OF GLEEVEC CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 27. COMPARATIVE REGION ANALYSIS OF VELCADE CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 28. COMPARATIVE REGION ANALYSIS OF IMBRUVICA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 29. COMPARATIVE REGION ANALYSIS OF IBRANCE CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 30. COMPARATIVE REGION ANALYSIS OF ZYTIGA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 31. COMPARATIVE REGION ANALYSIS OF ALIMTA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 32. COMPARATIVE REGION ANALYSIS OF XTANDI CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 33. COMPARATIVE REGION ANALYSIS OF TARCEVA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 34. COMPARATIVE REGION ANALYSIS OF PERJETA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 35. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, 2016 AND 2023 ($MILLION)
FIGURE 36. ABBVIE: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. ASTELLAS: NET SALES, 2015-2017 ($MILLION)
FIGURE 40. ASTELLAS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. BMS: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. BMS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. BMS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 45. CELGENE: NET SALES, 2015-2017 ($MILLION)
FIGURE 46. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 47. CELGENE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 48. ELI LILLY: NET SALES, 2015-2017 ($MILLION)
FIGURE 49. ELI LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 50. ELI LILLY: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 51. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 52. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 53. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 54. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 55. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 56. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 57. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 58. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 59. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 60. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 61. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 62. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 63. PFIZER NET SALES, 2015-2017 ($MILLION)
FIGURE 64. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 65. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
